<?xml version="1.0" encoding="UTF-8"?>
<p>We hypothesized that if the 
 <italic>cis</italic>‐acting and 
 <italic>trans</italic>‐acting spatial eQTLs (centered on 
 <italic>GBA</italic>) control modifier genes, then these genes should be epistatic with their products acting in the same or complementary pathways to the 
 <italic>GBA</italic>‐encoded GCase. Therefore, we performed pathway analyses and literature data mining on the 143 potential modifier genes. Collectively, these analyses revealed that 24% (n = 35) of the potential modifier genes have an association with PD or a related pathway (Supplementary Fig. 
 <xref rid="mds28144-supitem-0002" ref-type="supplementary-material">2</xref>b, Supplementary Table 
 <xref rid="mds28144-supitem-0006" ref-type="supplementary-material">4</xref>). Of these genes, 4 (
 <italic>DNAJC6</italic> [
 <italic>PARK19</italic>], 
 <italic>SYT11, SNAP91</italic> [
 <italic>AP180</italic>], 
 <italic>EPS15</italic>) showed enrichment involving synaptic vesicle formation and recycling, with 
 <italic>DNAJC6</italic> and 
 <italic>SYT11</italic> previously associated with PD.
 <xref rid="mds28144-bib-0046" ref-type="ref">
  <sup>46</sup>
 </xref>, 
 <xref rid="mds28144-bib-0047" ref-type="ref">
  <sup>47</sup>
 </xref>, 
 <xref rid="mds28144-bib-0048" ref-type="ref">
  <sup>48</sup>
 </xref>, 
 <xref rid="mds28144-bib-0049" ref-type="ref">
  <sup>49</sup>
 </xref>, 
 <xref rid="mds28144-bib-0050" ref-type="ref">
  <sup>50</sup>
 </xref> Nine genes had known neuronal functions (Supplementary Table 
 <xref rid="mds28144-supitem-0006" ref-type="supplementary-material">4</xref>), and notably 23% (33 of 143) of the modifier genes were identified as being druggable targets (Supplementary Table 
 <xref rid="mds28144-supitem-0006" ref-type="supplementary-material">5</xref>).
</p>
